InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Minerva Neurosciences, Inc.

NERV Clue Score47
United States Fiscal year ends December CIK 0001598646
$3.18 -1.24% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $3.18 +127.14% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 12 Oct 2016. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2016Operating income−30.2Net income−31.0Fiscal year 2017Revenue0.0Operating income−41.2Net income−31.5Fiscal year 2018Revenue0.0Operating income−51.7Net income−50.2Fiscal year 2019Revenue0.0Operating income−75.9Net income−72.2EPS, diluted−1.85Fiscal year 2020Revenue0.0Operating income1.8Net income1.9EPS, diluted0.05Fiscal year 2021Revenue0.0Operating income−45.4Net income−49.9 −2,671.4%EPS, diluted−9.35Fiscal year 2022Revenue0.0Operating income−25.2Net income−32.1EPS, diluted−6.01Fiscal year 2023Revenue0.0Operating income−23.1Net income−30.0EPS, diluted−4.61Fiscal year 2024Revenue0.0Operating income−21.8Net income1.4EPS, diluted0.19Fiscal year 2025Operating income−15.1Net income−293.4 −20,492.7%EPS, diluted−34.67
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue n/a 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 n/a
Growth
Operating income −30.2 −41.2 −51.7 −75.9 1.8 −45.4 −25.2 −23.1 −21.8 −15.1
Net income −31.0 −31.5 −50.2 −72.2 1.9 −49.9 −32.1 −30.0 1.4 −293.4
Growth −2,671.4% −20,492.7%
EPS, diluted n/a n/a n/a −1.85 0.05 −9.35 −6.01 −4.61 0.19 −34.67

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2016Operating cash flow−25.7Fiscal year 2017Operating cash flow3.1Capital expenditure−0.1Free cash flow3.0Buybacks−0.0Fiscal year 2018Operating cash flow−41.9Fiscal year 2019Operating cash flow−43.4Fiscal year 2020Operating cash flow−33.8Fiscal year 2021Operating cash flow−24.6Fiscal year 2022Operating cash flow−24.6Capital expenditure−0.0Free cash flow−24.7Fiscal year 2023Operating cash flow−14.8Fiscal year 2024Operating cash flow−19.6Fiscal year 2025Operating cash flow−13.5
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −25.7 3.1 −41.9 −43.4 −33.8 −24.6 −24.6 −14.8 −19.6 −13.5
Capital expenditure n/a −0.1 n/a n/a n/a n/a −0.0 n/a n/a n/a
Free cash flow n/a 3.0 n/a n/a n/a n/a −24.7 n/a n/a n/a
Growth
Buybacks n/a −0.0 n/a n/a n/a n/a n/a n/a n/a n/a

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2016Cash83.0Shareholders’ equity106.0Fiscal year 2017Cash26.1Shareholders’ equity131.6Fiscal year 2018Cash50.2Shareholders’ equity90.3Fiscal year 2019Cash21.4Shareholders’ equity27.8Fiscal year 2020Cash25.4Shareholders’ equity52.7Fiscal year 2021Cash60.8Shareholders’ equity8.0Fiscal year 2022Cash36.1Shareholders’ equity−20.0Fiscal year 2023Cash40.9Shareholders’ equity−28.5Fiscal year 2024Cash21.4Shareholders’ equity−25.7Fiscal year 2025Cash82.3Shareholders’ equity−140.7
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 83.0 26.1 50.2 21.4 25.4 60.8 36.1 40.9 21.4 82.3
Shareholders’ equity 106.0 131.6 90.3 27.8 52.7 8.0 −20.0 −28.5 −25.7 −140.7

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Cash flow

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2016 31 Dec 2016 FY2017 31 Dec 2017 FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021† 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Operations
−25.7 3.1 −41.9 −43.4 −33.8 −24.6 −24.6 −14.8 −19.6 −13.5
Growth −1,456.1%
0.0 0.0 0.0 0.0 0.0 n/a n/a n/a n/a n/a
Investment
n/a −0.1 n/a n/a n/a n/a −0.0 n/a n/a n/a
calc n/a 3.0 n/a n/a n/a n/a −24.7 n/a n/a n/a
Growth
calc n/a n/a n/a n/a n/a n/a −4.62 n/a n/a n/a
n/a −107.2 69.5 14.1 24.5 n/a −0.0 0.0 0.0 0.0
Financing
n/a 47.2 −3.3 0.5 13.2 60.0 −0.0 19.6 n/a 74.5
n/a −0.0 n/a n/a n/a n/a n/a n/a n/a n/a

† The diluted share count jumps at 2021, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Lines marked calc are worked out here from filed figures; point at one for how. Capital expenditure, dividends and buybacks are shown as money out, so negative.